This panel includes non-small cell lung cancer (NSCLC), breast, head and neck, colorectal, pancreatic, melanoma, ovarian, leukemia, and lymphoma cancer cell lines which contain common genomic alterations in cancer (including mutations on TP53, RAS, BRAF, and/or PIK3CA) (Supplementary Table 3). This evidence concerns the gene TP53 and melanoma.